Plasma pharmacokinetics of quinocetone in ducks after oral and intravenous administration.

Abstract

Quinocetone (QCT), an antimicrobial growth promoter, is widely used in food-producing animals. However, information about pharmacokinetics (PK) of QCT in ducks still remains unavailable up to now. In this study, QCT and its major metabolites (1-desoxyquinocetone, di-desoxyquinocetone and 3-methyl-quinoxaline-2-carboxylic) in ducks were studied using a simple and sensitive UHPLC-MS/MS assay. Twenty ducks were divided into two groups. (n=10/group). One group received QCT by oral administration at dose of 40mg/kg while another group received QCT intravenously at 10mg/kg. Plasma samples were collected at various time points from 0 to 96hr. QCT and its major metabolites in duck plasma samples were extracted by 1ml acetonitrile and detected by UHPLC-MS/MS, with the gradient mobile phase that consisted of 0.1% formic acid in water (A) and acetonitrile (B). A noncompartment analysis was used to calculate the PK parameters. The results showed that following oral dosing, the peak plasma concentration (Cmax ) of QCT was 32.14ng/ml and the area under the curve (AUCINF_obs) was 233.63 (hng)/ ml. Following intravenous dosing, the Cmax , AUCINF_obs and Vss_obs were 96.70ng/ml, 152.34 (hng)/ ml and 807.00L/kg, respectively. These data indicated that the QCT was less absorbed in vivo following oral administration, with low bioavailability (38.43%). QCT and its major metabolites such as 1-desoxyquinocetone and 3-methyl-quinoxaline-2-carboxylic were detected at individual time points in individual ducks, while the di-desoxyquinocetone was not detected in all time points in all ducks. This study enriches basic scientific data about pharmacokinetics of QCT in ducks after oral and intravenous administration and will be beneficial for clinical application in ducks.